Novo Nordisk sees more to GLP-1's future in $600M pact with Flagship's Metaphore

Novo Nordisk is pairing up with another Flagship-founded biotech to create new obesity medications, and GLP-1 remains in the frame.

The Danish pharma giant, which leads the GLP-1 field alongside Eli Lilly, will tap into the “molecular mimicry” work at Metaphore Biotechnologies to make one or two obesity management therapeutics, the companies said Thursday morning.

Novo will deliver up to $600 million in upfront payments and biobucks to Metaphore and Flagship’s Pioneering Medicines. Novo and Pioneering Medicines have a broad relationship that also includes an obesity pact with Omega Therapeutics.

Preview

来源: EndPoints

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP

LOG IN

BECOME A PREMIUM SUBSCRIBER

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。